share_log

EyePoint Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

EyePoint Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

EyePoint Pharmaceuticals | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/08 14:13

Moomoo AI 已提取核心信息

EyePoint Pharmaceuticals reported Q2 2024 total revenues of $9.5 million, a 4% increase year-over-year, driven by $7.8 million in license and collaboration revenue. Product sales declined to $1.1 million from $5.3 million last year following the Alimera YUTIQ licensing agreement. Net loss widened to $30.8 million from $22.9 million in Q2 2023.Research and development expenses increased 90% to $29.8 million, reflecting a $5 million milestone payment for Phase 2 trial completion and increased clinical development activities for DURAVYU. The company maintained a strong balance sheet with $280.2 million in cash and investments as of June 30, 2024, expected to fund operations through Phase 3 wet AMD topline data in 2026.The company received an FDA Warning Letter in July 2024 regarding YUTIQ manufacturing at its Watertown facility, requiring implementation of additional control procedures. Management believes YUTIQ supply should not be materially interrupted and other products in development, including DURAVYU, are not impacted. The company completed enrollment in the Phase 2 VERONA trial for diabetic macular edema and aligned with FDA on Phase 3 trials for wet AMD.
EyePoint Pharmaceuticals reported Q2 2024 total revenues of $9.5 million, a 4% increase year-over-year, driven by $7.8 million in license and collaboration revenue. Product sales declined to $1.1 million from $5.3 million last year following the Alimera YUTIQ licensing agreement. Net loss widened to $30.8 million from $22.9 million in Q2 2023.Research and development expenses increased 90% to $29.8 million, reflecting a $5 million milestone payment for Phase 2 trial completion and increased clinical development activities for DURAVYU. The company maintained a strong balance sheet with $280.2 million in cash and investments as of June 30, 2024, expected to fund operations through Phase 3 wet AMD topline data in 2026.The company received an FDA Warning Letter in July 2024 regarding YUTIQ manufacturing at its Watertown facility, requiring implementation of additional control procedures. Management believes YUTIQ supply should not be materially interrupted and other products in development, including DURAVYU, are not impacted. The company completed enrollment in the Phase 2 VERONA trial for diabetic macular edema and aligned with FDA on Phase 3 trials for wet AMD.
EyePoint Pharmaceuticals报告2024年第二季度总营业收入为950万美元，同比增长4%，主要得益于780万美元的许可和合作收入。产品销售从去年的530万美元下降至110万美元，原因是Alimera YUTIQ许可协议影响。净亏损扩大至3080万美元，之前为2023年第二季度的2290万美元。研发费用增加90%，达到2980万美元，其中包含500万美元的里程碑付款，用于第二阶段试验的完成，以及对DURAVYU的临床开发活动的增加。截至2024年6月30日，公司保持了强大的资产负债表，现金和投资总额为28020万美元，预计可支持公司通过2026年第三阶段湿性AMD顶线数据的运...展开全部
EyePoint Pharmaceuticals报告2024年第二季度总营业收入为950万美元，同比增长4%，主要得益于780万美元的许可和合作收入。产品销售从去年的530万美元下降至110万美元，原因是Alimera YUTIQ许可协议影响。净亏损扩大至3080万美元，之前为2023年第二季度的2290万美元。研发费用增加90%，达到2980万美元，其中包含500万美元的里程碑付款，用于第二阶段试验的完成，以及对DURAVYU的临床开发活动的增加。截至2024年6月30日，公司保持了强大的资产负债表，现金和投资总额为28020万美元，预计可支持公司通过2026年第三阶段湿性AMD顶线数据的运营。公司于2024年7月收到了FDA的警告信，涉及其Watertown工厂的YUTIQ制造，要求实施额外的控制程序。管理层认为，YUTIQ的供应不应受到实质性干扰，其他在开发中的产品，包括DURAVYU，亦不受影响。公司完成了糖尿病性黄斑水肿第二阶段VERONA试验的入组，并与FDA就湿性AMD的第三阶段试验达成一致。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 99.455
    bluebird bio
    BLUE
    -- 4.980
    NLS Pharmaceutics
    NLSP
    -- 1.4956
    Tonix Pharmaceuticals
    TNXP
    -- 22.6800
    Conduit Pharmaceuticals
    CDT
    -- 1.000
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点